European CHMP recommends paediatric license extension of teriflunomide (Aubagio) for treatment of relapsing remitting multiple sclerosis

The proposed license extension is for paediatric patients aged 10 years and older with relapsing remitting multiple sclerosis.

Source:

European Medicines Agency